MOLECULERA BIOSCIENCES, INC.
OKLAHOMA CITY, OK

Moleculera Biosciences, Inc., originally founded as Molectura Labs, Inc. in Oklahoma City, OK, with an incorporation date of June 12, 2013, is a fully-certified and fully-accredited clinical laboratory registered with CLIA (Clinical Laboratory Improvement Amendments) and COLA (Commission on Laboratory Accreditation). The company specializes in providing independent laboratory testing to support the diagnosis and treatment of perplexing Neuropsychiatric Disorders such as Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection (PANDAS). Under the leadership of President and CEO Dr. Craig Shimasaki and Chief Scientific Officer Dr. Madeleine Cunningham, along with CFO Fred E Hiller, Moleculera Labs offers the exclusive Cunningham Panel™, a collection of five high complexity tests known for assisting physicians in diagnosing neuropsychiatric disorders. This panel is a result of over a decade of research initiated by significant work at the National Institute of Mental Health (NIMH) and embodies Dr. Cunningham's extensive research on Sydenham’s chorea and PANDAS. Moleculera Labs, headquartered at 755 Research Parkway, Suite 410, Oklahoma City, OK 73104, prioritizes compassionate care for patients suffering from treatable autoimmune neuropsychiatric diseases. Their sole testing panel aims to provide comprehensive diagnostic information with a processing time of approximately three to four weeks. In terms of financial considerations, Moleculera Labs allows insurance claims and reimbursement processes on behalf of the patient, though they operate as an 'out-of-network' provider. Moleculera Labs is committed to affordability and accessibility in their testing services and, recognizing the potential financial limitations faced by some families, conducts case-by-case assessments to ensure necessary diagnostic tests are accessible. Their initiative extends beyond clinical science to advocacy, guiding parents through insurance procedures through resources such as Insurance Reimbursement FAQs and an Insurance Coverage Checklist. As of April 19, 2024, Moleculera Labs underwent a name change from Molectura Labs, Inc., reflecting its status under the most recent amendment. The company's dedication to helping those affected by autoimmune neurologic conditions is not only evident in their scientific endeavors but also through their commitment towards providing hope and support to families navigating these challenges. For more information on Moleculera Biosciences, Inc., please visit their website: moleculeralabs.com or contact them at (405) 239-5250 or (405) 239-5255.